N/A N=5 Vagal Nerve Stimulation for Treatment Resistant Major Depression
Major Depressive Disorder
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) at 3 Months — 12.3 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 Noninvasive Vagus Nerve Stimulation (VNS) for Neuromotor Adaptations
Healthy Young Adults
Primary: Visuomotor Skill — 1; 1; 0.870; 0.969 Ratio of the baseline value — p=0.0096
N/A N=27 Vagus Nerve Stimulation: Treatment for Gulf Veterans With Gulf War Illness
Pain · Migraine
Primary: Visual Analog Scale (VAS) to Assess Change of Widespread Pain — 4.70; 5.40; 5.43; 3.56 Units on a scale — p=0.47
N/A N=20 Vagus Nerve Stimulation: Integration of Behavior and Cardiac Modulation
Major Depressive Disorder
Primary: Brain Activity Changes (Average Differences in Beta Weights From Significantly Activated Regions: Post-stimulation Minus Pre-stimulation) Evaluated Using Functional…
N/A N=49 Non-invasive Vagal Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients With Gastroparesis and Related Disorders
Chronic Unexplained Nausea and Vomiting · Gastroparesis
Primary: Average Daily Use of Rescue Medications for Exacerbation of Nausea/Vomiting. — 1.186; 0.551; 0.754; 0.447 medications/day
N/A N=30 Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus
Tinnitus
Primary: Number of Participants With Serious Adverse Events — 1; 2 participants
Phase 3 N=56 Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder
PostTraumatic Stress Disorder
Primary: Level of Interleukin-6 (IL6) — 0.88; 0.84; 1.77; 2.11 pg/ml
N/A N=17 Vagus Nerve Stimulation as Treatment for Long Covid
Long COVID · Chronic Fatigue Syndrome
Primary: Number of Participants With Treatment Success — 8 Participants
N/A N=1 Optimization of VNS in Epileptic Patients to Induce Cardioprotection
Epilepsy · Sudden Cardiac Death
Primary: Change in Seizure Frequency or Duration Via a Routine Seizure History Used in Clinical Practice.
N/A N=62 Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation
Epilepsy · Seizures
Primary: Percent Patients Reaching the Defined Target Dose — 18; 9; 12 Participants
N/A N=108 Pivotal Study of VNS During Rehab After Stroke (VNS-REHAB)
Cerebrovascular Stroke · Upper Extremity Paresis
Primary: Fugl-Meyer Assessment, Upper Limb (FMA-UE) Average Change — 5.0; 2.4 units on a scale — p=0.0014
N/A N=59 Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation
Mild Cognitive Impairment
Primary: Rey Auditory Verbal Learning Test (Total Delayed Recall) — 6.43; 7.83 score on a scale — p=0.11
N/A N=40 Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
Acute Ischemic Stroke
Primary: Interleukin - 1b - Changes and Differences in the Levels — -0.222; 0.327 percent change/day — p=0.24
N/A N=136 Vagus Nerve Stimulation and Stress Reduction Training for Migraine
Migraine
Primary: Brain Activity Changes in Migraine Patients in Response to Treatment — -0.249; 0.679; 0.680; 1.06 Log ratio % signal change (Insula/Sp5)
N/A N=18 Vagal Nerve Stimulation for Post COVID Fatigue
Post COVID Syndrome · Fatigue · Headache
Primary: Change in Post-COVID Functional Status Score — 0.1; 0.3 units on a scale — p=0.544
Phase 4 N=331 Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses
Depression
Primary: Inventory of Depressive Symptomatology-Clinician Administered (IDS-C) Mean Change From Baseline to Week 22 of the Acute Phase (ITT Population). — -9.96; -10.29; -10.30…
N/A N=47 Auricular Neurostimulation for Cyclic Vomiting Syndrome
Cyclic Vomiting Syndrome · Abdominal Migraine
Primary: Rhodes Index of Nausea, Vomiting & Retching (INVR) — 3.25; 5.80; 10.43; 0.75 score on a scale
N/A N=7 Vagal Nerve Stimulation and Glucose Metabolism
Type 2 Diabetes · Obesity · Gastric Emptying
Primary: Disposition Index — 703; 532 10^-14dl/kg/min^2 per pmol/l
N/A N=150 Non-invasive Neurostimulation of the Vagus Nerve for the Treatment of Cluster Headache
Cluster Headache
Primary: Number of Participants With Repsonse to Treatment — 14; 16; 57; 44 Participants
N/A N=31 Transcutaneous Vagus Nerve Stimulation (taVNS) Dosage Study 1
Healthy
Primary: Tolerability Measured by Tolerability Questionnaire — 2.2; 2.2 score on a scale
Phase 1 N=19 Non-invasive Vagal Nerve Stimulation in Alcohol Use Disorder
Alcohol Use Disorder
Primary: Treatment Acceptability Questionnaire (TAQ) — 5.7; 6.4 score on a scale
Phase 2 N=50 External Trigeminal Nerve Stimulation for Epilepsy
Epilepsy · Seizure Disorders
Primary: 50% Responder Rate — 40.5; 15.6 percentage of participants
N/A N=22 VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)
Epilepsy
Primary: Estimate the Effect Size Associated With Objective Measures and Patient Self-reports of Clinical Outcomes Including Seizure Frequency, Seizure Severity, Seizure…
N/A N=26 Magnetic Stimulation to Treat VT Storm
Ventricular Tachycardia
Primary: Ventricular Tachycardia - Incidence of Ventricular Tachycardia on Inpatient Telemetry Monitoring — 7; 4 Participants
N/A N=33 taVNS in Mild to Moderate Parkinson's Disease
Parkinson Disease
Primary: Change in Motor Function Score as Assessed by Modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III — 0.72; 0.01 score on a…
Phase 2 N=36 Transcutaneous Vagus Nerve Stimulation (tVNS) and Robotic Training to Improve Arm Function After Stroke
Stroke · Cerebrovascular Accident (CVA) · Hemiparesis
Primary: Median Absolute Change From Baseline in Electromyographic (EMG) Peak Amplitude of the Bicep/Tricep — 22.310; 7.010; 16.070; 10.055 percentage of MVC — p=0.002
N/A N=115 Efficacy of Ear Neurostimulation for Adolescents With Functional Abdominal Pain
Functional Disorder of Intestine · Nausea Persistent
Primary: Pain Frequency-Severity-Duration Scale (PFSD) Score — 5.0; 7.0 units on a scale — p=0.003
N/A N=12 Noninvasive VNS to Facilitate Excitability in Motor Cortex
Stroke · Stroke Sequelae · Motor Activity
Primary: Safety of Combined taVNS and TMS — 0 Participants
N/A N=17 VNS During Rehabilitation for Improved Upper Limb Motor Function After Stroke
Stroke · Upper Limb Deficits
Primary: Change in Upper Extremity Fugl-Meyer (UEFM) — 7.6; 5.3 units on a scale
N/A N=22 Combining VNS With PT Interventions for Individuals With PD
Parkinson Disease
Primary: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III — 31.00; 36.70; 25.1; 26.8 Scores on a scale